title: Risks associated with tiotropium in chronic obstructive pulmonary disease: overview of the evidence to date.
abstract: Tiotropium is a long-acting inhaled anticholinergic agent that is widely used in the treatment of chronic obstructive pulmonary disease (COPD). It was initially launched as the tiotropium HandiHaler formulation, but this was followed by a newer version based on a potentially more efficient drug delivery device, known as Respimat. This Respimat formulation is available worldwide but has not yet succeeded in gaining regulatory approval in the USA. In the past few years, the adverse effects profile of tiotropium has come under close scrutiny owing to concerns about the possibility of urinary and cardiovascular adverse effects. These concerns appeared to have been alleviated following the publication of data from the Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial, which was a large trial of 4 years' duration. This trial did not show any excess myocardial infarction, renal or urinary adverse events with tiotropium compared with placebo. However, the risk of urinary retention has been in the spotlight again following publication of two observational studies reporting a significantly increased risk of urinary retention in men recently started on inhaled anticholinergics, especially when prostatic hyperplasia coexists. More recently, a meta-analysis of mortality data for the tiotropium Respimat formulation raised the possibility of an increased risk of death, including death from cardiovascular causes. It is unclear if the more efficient drug delivery offered by the Respimat device is hitting a different part of the dose-toxicity curve. In the absence of any evidence of superior clinical efficacy with tiotropium Respimat compared with tiotropium HandiHaler, some experts have argued that there is no compelling reason to choose the Respimat formulation given the new uncertainties about its safety profile.
authors.affiliation: Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK.
authors.forename: Yoon K
authors.initials: YK
authors.lastname: Loke
authors.affiliation: Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Sonal
authors.initials: S
authors.lastname: Singh
keywords: cardiovascular event; formulation; mortality; risk; safety; tiotropium
references.citation: Thorax. 2006 Oct;61(10):854-62
references.pmid: 16844726
references.citation: Am J Respir Crit Care Med. 2009 Nov 15;180(10):948-55
references.pmid: 19729663
references.citation: Chest. 2010 Jan;137(1):20-30
references.pmid: 19592475
references.citation: N Engl J Med. 2010 Jul 29;363(5):493-4; author reply 494-5
references.pmid: 20666630
references.citation: Respir Med. 2011 Apr;105(4):571-9
references.pmid: 21227674
references.citation: Drug Saf. 2007;30(12):1151-60
references.pmid: 18035867
references.citation: Arch Intern Med. 2011 May 23;171(10):914-20
references.pmid: 21606096
references.citation: BMJ. 2011 Jun 14;342:d2970
references.pmid: 21672998
references.citation: DICP. 1991 Sep;25(9):939-40
references.pmid: 1835224
references.citation: Am J Respir Crit Care Med. 2002 Aug 1;166(3):333-9
references.pmid: 12153966
references.citation: Ann Intern Med. 2008 Sep 16;149(6):380-90
references.pmid: 18794557
references.citation: N Engl J Med. 1997 Aug 21;337(8):536-42
references.pmid: 9262498
references.citation: JAMA. 2008 Sep 24;300(12):1439-50
references.pmid: 18812535
references.citation: Ann Intern Med. 2011 May 3;154(9):583-92
references.pmid: 21536937
references.citation: J Clin Epidemiol. 1996 Apr;49(4):395-400
references.pmid: 8621989
references.citation: Chest. 2006 Dec;130(6):1695-703
references.pmid: 17166984
references.citation: Respir Med. 2009 Oct;103(10):1421-9
references.pmid: 19556116
references.citation: Expert Opin Drug Saf. 2010 Sep;9(5):783-92
references.pmid: 20565229
references.citation: Chest. 2012 Jan;141(1):81-86
references.pmid: 21799028
references.citation: N Z Med J. 2011 Jun 24;124(1337):117-8
references.pmid: 21946887
references.citation: Am J Respir Crit Care Med. 2003 Mar 1;167(5):801; author reply 801-2
references.pmid: 12598223
references.citation: BJU Int. 2011 Apr;107(8):1265-72
references.pmid: 20880196
references.citation: N Engl J Med. 2008 Oct 9;359(15):1543-54
references.pmid: 18836213
references.citation: Eur J Epidemiol. 2007;22(4):267-72
references.pmid: 17342451
references.citation: Clin Trials. 2011 Oct;8(5):559-70
references.pmid: 21878445
references.citation: BMJ. 2011 Jun 14;342:d3215
references.pmid: 21672999
references.citation: Int J Chron Obstruct Pulmon Dis. 2011;6:129-39
references.pmid: 21468167
references.citation: BMJ. 2010 Feb 19;340:c833
references.pmid: 20172927